Aoxing Pharmaceutical Company, Inc. · OTC:AOXG
Aoxing Pharmaceutical — Investor Presentation (October 2015)
16 slides from Aoxing Pharmaceutical's investor presentation, Oct 21, 2015
Slide 1: Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. NYSE MKT: AXN, Pain-Management , Psychiatric Treatment, Addiction Treatment, Weight Loss Treatment Narcotic Pharmaceuticals State Designated Narcotics Manufacturer
Slide 2: Forward-looking Statement
Forward-looking Statement = Included in this presentation are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. Such forward-looking statements involve known and unknown risks, uncertainties and other factors w
Slide 3: Investment Highlights
Investment Highlights + Unique postioning es fig value igh margin pain-management, psychiatric treatment, weight les treatment and addiction tretment pharmaceutical = S3pacl rugs painmanagement products. adcton treatment dig, 2pychitc dg, 2 weight om rug. These product fil the ‘market gaps in China.
Slide 4: Introduction
Introduction Fast growing R&D, manufacturer, and distributor of narcotic Administration pain-management, psychiatric, weight loss and addiction ‘ treatment medicines in China Founded in 2000, with sales office in Shijiazhuang and production facilities in Xin Le city, Hebei province, Aoxing has the l
Slide 5: Production Facilities
Production Facilities China’s Largest and Most Advanced Narcotic Pharmaceutical R&D Facilities (300 Acres)
Slide 6: Business Milestones
Business Milestones 2000 - Hebei Aoxing Pharmaceutical Co., Ltd.,(Hebel Aoxing) was incorporated and began engaging in producing and distribution of various narcotics, psychiatric, weight loss and pain-management products in China 2006 ~ Hebel Aoxing restructured to be a 95% subsidiary of Aoxing and
Slide 7: Current Drug Offering
Current Drug Offering Dr Usage Zhongtong’an Capsule jrasmn IM Be BEE Yigigiangshen Granule Nourish 2 BURL vitality Sole producer, OTC Inflammation Sole producer Shaoshanglingding Spray RRA Burns Sole Producer Total 138 products, including 9 types of formulations.
Slide 8: Distribution Key Markets
Distribution 5 Key Markets + 600 specialty hospitals + 3500 hospitals + 30000 drug stores Distribution Cha + Direct sales + Retailors + KAmodel + Provincial City Govern
Slide 9: SFDA-Approved R&D Narcotic, Addiction Treatment Drug List (First Part)
SFDA-Approved R&D Narcotic , Addiction Treatment Drug List (First Part) Drug Indication Opportunity Tilidine HCl (Tablets) Moderate to severe pain No production in China ‘Compound Tilidine HCI Moderate to severe pain No production in China (Capsule) ‘Oxycodone (Capsule) Moderate to severe pain Top 2
Slide 10: Narcotic Drug R&D Schedule (2002-2015 First Part)
Narcotic Drug R&D Schedule (2002-2015 First Part) R&D Progress Indication Production Pre-Clinical —Clinical«=«=_Approved Production Registration Moderate to severe Tiliine Tablet 2015 pain mptaerntie | Siem - _ Onyeodone capsule | Mosenisiossee 7 2016 Buprenorphine / | wHo recommended [Naloxone Subl
Slide 11: SFDA-Approved R&D Psychiatric, Weight Loss Treatment Drug List (Second Part)
‘SFDA-Approved R&D Psychiatric, Weight Loss Treatment Drug List (Second Part) Drug Indication Opportunity Lorcaserin Hydrochloride (API) Weight loss treatment. No production in China Lorcaserin Hydrochloride (Tablet) Weight loss treatment No production in China Caffeine (Tablet) Combat fatigue and N
Slide 12: Psychiatric, Weight Loss Treatment Drugs R&D Schedule (Second Part)
Psychiatric, Weight Loss Treatment Drugs R&D Schedule (Second Part) R&D Progress Indication Pre-Clinical Production Treat obesity that may be related to diabetes, Lorcaserin Hydrochloride (API) Ready 2017 high cholesterol or high blood pressure Treat obesity that may be related to diabetes, | Ready
Slide 13: China Narcotic Drug Market: Barrier to Entry
China Narcotic Drug Market: Barrier to Entry CFDA Production License Quota for Narcotic Drugs + API: up to 2 license holders + Narcotic Preparation Varieties: up to 3 license holders Varieties Containing Narcotic Preparations: up to 7 license holders “Regulation for Narcotic and CNS Drugs” Order No.
Slide 14: Narcotic Drug Positioning
Narcotic Drug Positioning + Cancer, post-operation, and other pains “Addiction treatment “AIDS prevention ‘Standard prescriptions «Patients *Acute / chronic conditios > Fast acting “Low reliance Safe “Over 500 state-owned sales channels sPrice elasticity “Government policies *Medical insurance “Long
Slide 15: Management
Management Zhengjiang Yue Wilfred Chow CFO Guirong Zhou R&D Peng Jiang Sale: ‘Mr. Yue once joined the army and founded Hebei Aoxing Pharmaceutical Group Company, the subsidiary of China ‘Aoxing Pharmaceutical Company Inc in China, in 2000. Prior tothe founding of Hebe! Aoxing, Mr. Yue was engaged in
Slide 16: Financials
Financials Period Ending June (USD '000) Fy13 Fyaa FyAs Revenues 10830 12,739 (25,481 Gross Margin 6,268 5814 19,792 % 57.9% 45.6% 77.7% OPEX 20,489 9149 11,097 ‘Net income (16,804) (8,216) 5,495 % N/A N/A 21.6% Cash 4,008 2,330 5,372 ‘Net Working Capital (9,811) (23,294) (20,144) Operating Cash Flo
Aoxing Pharmaceutical Company — Investor Presentation (October 2015) on 6ix